 Stacey Gundry
Concepts (358)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 64 | 2001 | 754 | 1.510 |
Why?
| | Transplantation, Heterologous | 19 | 2000 | 194 | 0.750 |
Why?
| | Heart Arrest, Induced | 8 | 1998 | 31 | 0.540 |
Why?
| | Graft Rejection | 31 | 2001 | 624 | 0.450 |
Why?
| | Tissue Donors | 11 | 1997 | 425 | 0.390 |
Why?
| | Myocardial Reperfusion | 3 | 1995 | 50 | 0.320 |
Why?
| | Heart Defects, Congenital | 16 | 2000 | 842 | 0.290 |
Why?
| | Coronary Disease | 5 | 1998 | 385 | 0.280 |
Why?
| | Pericardium | 3 | 1997 | 55 | 0.280 |
Why?
| | Esophageal Perforation | 2 | 1996 | 15 | 0.240 |
Why?
| | Graft Survival | 14 | 2000 | 535 | 0.240 |
Why?
| | Heart Valve Prosthesis | 4 | 1997 | 114 | 0.230 |
Why?
| | Coronary Artery Bypass | 3 | 1998 | 234 | 0.220 |
Why?
| | Coronary Vessels | 4 | 1997 | 248 | 0.210 |
Why?
| | Cardiac Catheterization | 4 | 1998 | 530 | 0.200 |
Why?
| | Echocardiography | 9 | 1998 | 642 | 0.180 |
Why?
| | Infant | 44 | 2001 | 9465 | 0.180 |
Why?
| | Cardiopulmonary Bypass | 6 | 1998 | 209 | 0.180 |
Why?
| | Reoperation | 12 | 2001 | 573 | 0.170 |
Why?
| | Postoperative Complications | 18 | 2000 | 2654 | 0.170 |
Why?
| | Papio | 16 | 2000 | 94 | 0.170 |
Why?
| | Sternum | 2 | 1998 | 24 | 0.170 |
Why?
| | Cardiac Surgical Procedures | 6 | 2000 | 530 | 0.170 |
Why?
| | Infant, Newborn | 37 | 2001 | 6079 | 0.170 |
Why?
| | Aortic Valve | 3 | 1998 | 351 | 0.160 |
Why?
| | Zebrafish | 3 | 2018 | 499 | 0.160 |
Why?
| | Iatrogenic Disease | 2 | 1997 | 67 | 0.160 |
Why?
| | Graft Occlusion, Vascular | 2 | 1998 | 40 | 0.150 |
Why?
| | Cardioplegic Solutions | 3 | 1995 | 6 | 0.150 |
Why?
| | Thoracotomy | 2 | 1998 | 75 | 0.150 |
Why?
| | Time Factors | 24 | 2000 | 6828 | 0.150 |
Why?
| | Echocardiography, Doppler, Color | 1 | 1997 | 37 | 0.140 |
Why?
| | Microsurgery | 1 | 1998 | 75 | 0.140 |
Why?
| | Tetralogy of Fallot | 2 | 1998 | 79 | 0.140 |
Why?
| | Ventricular Outflow Obstruction | 2 | 1996 | 43 | 0.140 |
Why?
| | DEAD-box RNA Helicases | 1 | 2018 | 76 | 0.140 |
Why?
| | Methotrexate | 10 | 2000 | 260 | 0.140 |
Why?
| | RNA, Ribosomal | 1 | 2018 | 168 | 0.140 |
Why?
| | Immunosuppressive Agents | 13 | 2000 | 890 | 0.130 |
Why?
| | Swine | 12 | 2000 | 775 | 0.130 |
Why?
| | Child, Preschool | 31 | 2001 | 11074 | 0.130 |
Why?
| | Follow-Up Studies | 17 | 1998 | 5131 | 0.130 |
Why?
| | Pulmonary Valve | 2 | 1996 | 97 | 0.120 |
Why?
| | Coronary Circulation | 2 | 1996 | 143 | 0.120 |
Why?
| | Fundoplication | 1 | 1995 | 53 | 0.120 |
Why?
| | Fontan Procedure | 1 | 1997 | 180 | 0.120 |
Why?
| | Survival Rate | 12 | 2000 | 1972 | 0.120 |
Why?
| | Protein Biosynthesis | 1 | 2018 | 433 | 0.120 |
Why?
| | Organ Transplantation | 1 | 1997 | 250 | 0.110 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2013 | 6 | 0.100 |
Why?
| | Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 11 | 0.100 |
Why?
| | Lymphocyte Subsets | 4 | 1996 | 87 | 0.100 |
Why?
| | Hypoplastic Left Heart Syndrome | 4 | 1998 | 121 | 0.100 |
Why?
| | Zebrafish Proteins | 2 | 2018 | 288 | 0.100 |
Why?
| | Splenectomy | 5 | 2000 | 62 | 0.100 |
Why?
| | Heart Ventricles | 4 | 2000 | 788 | 0.090 |
Why?
| | Humans | 71 | 2013 | 137585 | 0.090 |
Why?
| | Muscle, Skeletal | 3 | 2018 | 1724 | 0.090 |
Why?
| | Animals | 32 | 2018 | 36940 | 0.090 |
Why?
| | Dystroglycans | 1 | 2011 | 6 | 0.090 |
Why?
| | Heart Diseases | 3 | 1993 | 346 | 0.090 |
Why?
| | Muscular Dystrophies | 1 | 2011 | 36 | 0.090 |
Why?
| | Child | 29 | 2001 | 21935 | 0.080 |
Why?
| | Macaca mulatta | 7 | 2000 | 166 | 0.080 |
Why?
| | Tissue and Organ Procurement | 6 | 1997 | 321 | 0.080 |
Why?
| | Animals, Newborn | 9 | 2000 | 844 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 341 | 0.080 |
Why?
| | Aorta, Thoracic | 3 | 2000 | 267 | 0.070 |
Why?
| | Cyclosporine | 10 | 2000 | 268 | 0.070 |
Why?
| | Myocardium | 7 | 1998 | 1002 | 0.070 |
Why?
| | Organ Preservation | 3 | 1993 | 102 | 0.070 |
Why?
| | Heart Failure | 3 | 2000 | 2236 | 0.070 |
Why?
| | Endothelium, Vascular | 5 | 2000 | 927 | 0.070 |
Why?
| | Mitral Valve | 2 | 1998 | 88 | 0.070 |
Why?
| | Proteins | 1 | 2013 | 1009 | 0.070 |
Why?
| | Thoracic Injuries | 2 | 2000 | 55 | 0.070 |
Why?
| | Survival Analysis | 9 | 1998 | 1325 | 0.070 |
Why?
| | Transplantation, Homologous | 6 | 2001 | 416 | 0.060 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 1998 | 141 | 0.060 |
Why?
| | Tacrolimus | 5 | 1997 | 199 | 0.060 |
Why?
| | Aged | 10 | 2000 | 23961 | 0.060 |
Why?
| | Hemodynamics | 6 | 2000 | 1113 | 0.060 |
Why?
| | Ventricular Function, Left | 5 | 1995 | 534 | 0.060 |
Why?
| | Heart | 3 | 1995 | 655 | 0.060 |
Why?
| | Male | 34 | 2011 | 67762 | 0.060 |
Why?
| | Goats | 7 | 2000 | 27 | 0.060 |
Why?
| | Wounds, Nonpenetrating | 2 | 2000 | 278 | 0.050 |
Why?
| | Female | 33 | 2011 | 73304 | 0.050 |
Why?
| | Resuscitation | 2 | 1997 | 251 | 0.050 |
Why?
| | Blood | 2 | 1995 | 107 | 0.050 |
Why?
| | Equipment Design | 2 | 1998 | 522 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 2 | 1996 | 560 | 0.050 |
Why?
| | Retrospective Studies | 19 | 2001 | 15657 | 0.050 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 1995 | 249 | 0.050 |
Why?
| | Treatment Outcome | 10 | 2001 | 10811 | 0.050 |
Why?
| | Carbon Dioxide | 2 | 1996 | 267 | 0.050 |
Why?
| | Adolescent | 15 | 2001 | 21513 | 0.050 |
Why?
| | Aorta | 3 | 2000 | 417 | 0.050 |
Why?
| | Mitral Valve Insufficiency | 3 | 1997 | 68 | 0.050 |
Why?
| | Sheep | 3 | 1993 | 856 | 0.050 |
Why?
| | Cause of Death | 4 | 1997 | 434 | 0.050 |
Why?
| | Body Temperature | 2 | 1993 | 222 | 0.040 |
Why?
| | Methylprednisolone | 6 | 2000 | 86 | 0.040 |
Why?
| | Heart Atria | 2 | 1992 | 137 | 0.040 |
Why?
| | Cardiomyopathies | 2 | 1997 | 350 | 0.040 |
Why?
| | Incidence | 6 | 2000 | 2804 | 0.040 |
Why?
| | Trisaccharides | 1 | 2000 | 2 | 0.040 |
Why?
| | Antigens, Heterophile | 1 | 2000 | 5 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 14 | 0.040 |
Why?
| | Polytetrafluoroethylene | 1 | 2000 | 23 | 0.040 |
Why?
| | Aortic Rupture | 1 | 2000 | 25 | 0.040 |
Why?
| | Transplantation Chimera | 1 | 2000 | 54 | 0.040 |
Why?
| | Antilymphocyte Serum | 5 | 2000 | 66 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2000 | 7635 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4295 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2847 | 0.040 |
Why?
| | Myocardial Contraction | 4 | 1993 | 341 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 2 | 1997 | 96 | 0.040 |
Why?
| | Oxygen | 2 | 1996 | 931 | 0.040 |
Why?
| | Lymphocyte Activation | 2 | 2000 | 1142 | 0.040 |
Why?
| | Rhizopus | 1 | 1999 | 5 | 0.040 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2000 | 66 | 0.040 |
Why?
| | Lung Abscess | 1 | 1999 | 7 | 0.040 |
Why?
| | Lung Diseases, Fungal | 1 | 1999 | 13 | 0.040 |
Why?
| | Mucormycosis | 1 | 1999 | 22 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2000 | 286 | 0.040 |
Why?
| | Adult | 10 | 2000 | 37929 | 0.040 |
Why?
| | Cell Adhesion | 1 | 2000 | 466 | 0.040 |
Why?
| | Hypothermia, Induced | 2 | 1998 | 80 | 0.040 |
Why?
| | Situs Inversus | 1 | 1998 | 3 | 0.040 |
Why?
| | Length of Stay | 2 | 1998 | 1215 | 0.040 |
Why?
| | Feasibility Studies | 3 | 1998 | 956 | 0.040 |
Why?
| | PAX2 Transcription Factor | 1 | 2018 | 8 | 0.040 |
Why?
| | Cell Nucleolus | 1 | 2018 | 17 | 0.040 |
Why?
| | Hospital Mortality | 3 | 2000 | 911 | 0.040 |
Why?
| | Age Factors | 6 | 1995 | 3295 | 0.040 |
Why?
| | Lymphocytes | 1 | 2000 | 397 | 0.040 |
Why?
| | Dermatologic Surgical Procedures | 1 | 1998 | 20 | 0.040 |
Why?
| | Suction | 1 | 1998 | 34 | 0.040 |
Why?
| | Heart Septal Defects | 1 | 1997 | 8 | 0.040 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 1998 | 42 | 0.030 |
Why?
| | Middle Aged | 9 | 2000 | 33479 | 0.030 |
Why?
| | Heart Septal Defects, Atrial | 1 | 1998 | 54 | 0.030 |
Why?
| | Myoblasts | 1 | 2018 | 84 | 0.030 |
Why?
| | Aortic Coarctation | 1 | 1998 | 83 | 0.030 |
Why?
| | Embryo, Nonmammalian | 1 | 2018 | 167 | 0.030 |
Why?
| | Death | 1 | 1998 | 119 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 1997 | 47 | 0.030 |
Why?
| | Muscle Development | 1 | 2018 | 111 | 0.030 |
Why?
| | Drainage | 1 | 1998 | 173 | 0.030 |
Why?
| | Azathioprine | 5 | 1998 | 54 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2018 | 240 | 0.030 |
Why?
| | Vena Cava, Inferior | 1 | 1997 | 71 | 0.030 |
Why?
| | Actuarial Analysis | 5 | 1996 | 27 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1998 | 179 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2000 | 385 | 0.030 |
Why?
| | United Kingdom | 1 | 1997 | 318 | 0.030 |
Why?
| | Patient Care Planning | 1 | 1997 | 157 | 0.030 |
Why?
| | Ethics, Medical | 1 | 1997 | 84 | 0.030 |
Why?
| | Surgical Flaps | 1 | 1997 | 130 | 0.030 |
Why?
| | Gastric Fundus | 1 | 1996 | 3 | 0.030 |
Why?
| | Myosins | 2 | 1993 | 135 | 0.030 |
Why?
| | Regeneration | 1 | 2018 | 197 | 0.030 |
Why?
| | Antibodies | 2 | 1997 | 410 | 0.030 |
Why?
| | Drug Therapy, Combination | 4 | 2000 | 1066 | 0.030 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 1998 | 180 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1998 | 257 | 0.030 |
Why?
| | Brain Death | 2 | 1993 | 46 | 0.030 |
Why?
| | Blood Pressure | 2 | 1993 | 1786 | 0.030 |
Why?
| | Morbidity | 1 | 1996 | 324 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2000 | 1996 | 0.030 |
Why?
| | Heart-Assist Devices | 1 | 2000 | 552 | 0.030 |
Why?
| | Research | 1 | 1997 | 451 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 1995 | 99 | 0.030 |
Why?
| | Arteriosclerosis | 1 | 1994 | 88 | 0.030 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 1995 | 137 | 0.030 |
Why?
| | Central Nervous System | 1 | 1996 | 258 | 0.030 |
Why?
| | Bioprosthesis | 1 | 1994 | 40 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 1998 | 660 | 0.030 |
Why?
| | Myosin Light Chains | 1 | 1993 | 26 | 0.030 |
Why?
| | Blood Gas Analysis | 1 | 1993 | 74 | 0.030 |
Why?
| | Aneurysm, False | 1 | 1993 | 48 | 0.030 |
Why?
| | Societies, Medical | 1 | 1997 | 820 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 1994 | 123 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 1994 | 238 | 0.030 |
Why?
| | Heart Septum | 1 | 1992 | 28 | 0.020 |
Why?
| | Protein Stability | 1 | 2013 | 176 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1997 | 1050 | 0.020 |
Why?
| | Syndrome | 2 | 1991 | 358 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1997 | 778 | 0.020 |
Why?
| | Transposition of Great Vessels | 1 | 1992 | 36 | 0.020 |
Why?
| | California | 4 | 1997 | 431 | 0.020 |
Why?
| | Catalysis | 1 | 2013 | 307 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 326 | 0.020 |
Why?
| | Body Weight | 2 | 1995 | 985 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 1993 | 131 | 0.020 |
Why?
| | Postoperative Care | 1 | 1993 | 261 | 0.020 |
Why?
| | Pulmonary Artery | 1 | 1997 | 1086 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 1993 | 192 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 1994 | 315 | 0.020 |
Why?
| | Myocardial Revascularization | 1 | 1990 | 73 | 0.020 |
Why?
| | Cardiomegaly | 1 | 1992 | 175 | 0.020 |
Why?
| | Peritoneal Dialysis | 1 | 1992 | 97 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2475 | 0.020 |
Why?
| | Whole-Body Irradiation | 2 | 2000 | 78 | 0.020 |
Why?
| | Point Mutation | 1 | 2011 | 235 | 0.020 |
Why?
| | Decision Trees | 1 | 1990 | 93 | 0.020 |
Why?
| | Temperature | 1 | 1993 | 679 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 240 | 0.020 |
Why?
| | Antibody Formation | 2 | 2000 | 298 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 2000 | 50 | 0.020 |
Why?
| | Mice | 2 | 2018 | 17787 | 0.020 |
Why?
| | CD2 Antigens | 2 | 2000 | 6 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1996 | 3556 | 0.020 |
Why?
| | Palliative Care | 2 | 1994 | 758 | 0.020 |
Why?
| | Mental Disorders | 1 | 1996 | 1077 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2181 | 0.020 |
Why?
| | Emergencies | 2 | 2000 | 164 | 0.020 |
Why?
| | Guanidines | 2 | 1997 | 39 | 0.020 |
Why?
| | Combined Modality Therapy | 2 | 2000 | 1236 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2900 | 0.020 |
Why?
| | Immunoglobulin M | 2 | 2000 | 289 | 0.020 |
Why?
| | Preoperative Care | 3 | 1994 | 362 | 0.020 |
Why?
| | Risk Factors | 6 | 1998 | 10388 | 0.020 |
Why?
| | Leukocytes | 2 | 2000 | 311 | 0.020 |
Why?
| | Motor Activity | 1 | 2011 | 718 | 0.020 |
Why?
| | Killer Cells, Natural | 2 | 2000 | 449 | 0.020 |
Why?
| | Cryopreservation | 2 | 1997 | 100 | 0.020 |
Why?
| | United States | 3 | 1997 | 14841 | 0.010 |
Why?
| | Myocardial Ischemia | 2 | 1999 | 263 | 0.010 |
Why?
| | Antigens, CD | 2 | 2000 | 521 | 0.010 |
Why?
| | Forecasting | 2 | 1998 | 389 | 0.010 |
Why?
| | Acute Kidney Injury | 1 | 1992 | 815 | 0.010 |
Why?
| | Contraindications | 2 | 1993 | 90 | 0.010 |
Why?
| | Hemorrhage | 2 | 2000 | 722 | 0.010 |
Why?
| | Recurrence | 2 | 1998 | 1060 | 0.010 |
Why?
| | Chi-Square Distribution | 2 | 1995 | 530 | 0.010 |
Why?
| | Pediatrics | 1 | 1991 | 1101 | 0.010 |
Why?
| | CD8 Antigens | 2 | 1994 | 75 | 0.010 |
Why?
| | Prognosis | 3 | 2000 | 4030 | 0.010 |
Why?
| | CD4 Antigens | 2 | 1994 | 141 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2000 | 4193 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1994 | 1910 | 0.010 |
Why?
| | Stroke Volume | 2 | 1995 | 612 | 0.010 |
Why?
| | Mutation | 1 | 2013 | 3958 | 0.010 |
Why?
| | Cytokines | 2 | 2000 | 2085 | 0.010 |
Why?
| | Pokeweed Mitogens | 1 | 2000 | 7 | 0.010 |
Why?
| | Extracorporeal Circulation | 1 | 2000 | 13 | 0.010 |
Why?
| | Constriction | 1 | 2000 | 47 | 0.010 |
Why?
| | Paraplegia | 1 | 2000 | 60 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 2 | 1992 | 417 | 0.010 |
Why?
| | Amphotericin B | 1 | 1999 | 31 | 0.010 |
Why?
| | Biopsy | 2 | 1994 | 1129 | 0.010 |
Why?
| | Elective Surgical Procedures | 1 | 2000 | 179 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 2000 | 268 | 0.010 |
Why?
| | Lymphatic Irradiation | 1 | 1998 | 10 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2000 | 1092 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1999 | 136 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 2000 | 474 | 0.010 |
Why?
| | Spleen | 1 | 2000 | 514 | 0.010 |
Why?
| | Epitopes | 1 | 2000 | 479 | 0.010 |
Why?
| | Fetal Blood | 1 | 2000 | 327 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 7604 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 852 | 0.010 |
Why?
| | Cattle | 1 | 2000 | 984 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1998 | 171 | 0.010 |
Why?
| | Angioplasty, Balloon | 1 | 1998 | 93 | 0.010 |
Why?
| | Euthanasia, Passive | 1 | 1997 | 2 | 0.010 |
Why?
| | Swine, Miniature | 1 | 1997 | 82 | 0.010 |
Why?
| | Death, Sudden, Cardiac | 1 | 1998 | 185 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 1998 | 686 | 0.010 |
Why?
| | Withholding Treatment | 1 | 1997 | 76 | 0.010 |
Why?
| | Safety | 1 | 1998 | 338 | 0.010 |
Why?
| | Random Allocation | 1 | 1997 | 353 | 0.010 |
Why?
| | Pressure | 1 | 1997 | 225 | 0.010 |
Why?
| | Perfusion | 1 | 1997 | 213 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1996 | 83 | 0.010 |
Why?
| | Disclosure | 1 | 1997 | 113 | 0.010 |
Why?
| | Ultrasonography | 1 | 2000 | 759 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2000 | 893 | 0.010 |
Why?
| | Body Surface Area | 1 | 1995 | 34 | 0.010 |
Why?
| | Linear Models | 1 | 1998 | 849 | 0.010 |
Why?
| | Cadaver | 1 | 1997 | 296 | 0.010 |
Why?
| | Fetus | 1 | 2000 | 806 | 0.010 |
Why?
| | Informed Consent | 1 | 1997 | 175 | 0.010 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 1995 | 12 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1996 | 247 | 0.010 |
Why?
| | Edema | 1 | 1996 | 130 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2000 | 1242 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1995 | 66 | 0.010 |
Why?
| | Necrosis | 1 | 1996 | 246 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1995 | 114 | 0.010 |
Why?
| | Organ Size | 1 | 1995 | 477 | 0.010 |
Why?
| | Heart Valve Diseases | 1 | 1996 | 151 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1994 | 22 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1995 | 329 | 0.010 |
Why?
| | Antigens, CD20 | 1 | 1994 | 29 | 0.010 |
Why?
| | Methods | 1 | 1994 | 65 | 0.010 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 1994 | 37 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 98 | 0.010 |
Why?
| | Treatment Failure | 1 | 1995 | 356 | 0.010 |
Why?
| | Cardiac Volume | 1 | 1994 | 13 | 0.010 |
Why?
| | Shock | 1 | 1995 | 98 | 0.010 |
Why?
| | Emergency Medical Services | 1 | 2000 | 552 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1994 | 154 | 0.010 |
Why?
| | Pericardial Effusion | 1 | 1994 | 19 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1998 | 1738 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 180 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1994 | 390 | 0.010 |
Why?
| | H-Y Antigen | 1 | 1993 | 7 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 1995 | 786 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1994 | 282 | 0.010 |
Why?
| | Histocompatibility | 1 | 1993 | 28 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 1995 | 252 | 0.010 |
Why?
| | Pulmonary Atelectasis | 1 | 1992 | 15 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 1994 | 216 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 289 | 0.010 |
Why?
| | Regression Analysis | 1 | 1995 | 1024 | 0.010 |
Why?
| | Myocarditis | 1 | 1994 | 100 | 0.010 |
Why?
| | Diastole | 1 | 1993 | 149 | 0.010 |
Why?
| | Systole | 1 | 1993 | 189 | 0.010 |
Why?
| | Ventricular Function | 1 | 1992 | 61 | 0.010 |
Why?
| | Cohort Studies | 2 | 1993 | 5742 | 0.010 |
Why?
| | Prednisone | 1 | 1993 | 240 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1994 | 275 | 0.010 |
Why?
| | Erythromycin | 1 | 1991 | 25 | 0.010 |
Why?
| | Ciprofloxacin | 1 | 1991 | 29 | 0.010 |
Why?
| | Confidence Intervals | 1 | 1992 | 329 | 0.010 |
Why?
| | Transforming Growth Factor alpha | 1 | 1991 | 57 | 0.010 |
Why?
| | Platelet-Derived Growth Factor | 1 | 1991 | 93 | 0.010 |
Why?
| | Gentamicins | 1 | 1991 | 54 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1995 | 1509 | 0.010 |
Why?
| | Heart Arrest | 1 | 1995 | 339 | 0.010 |
Why?
| | B-Lymphocyte Subsets | 1 | 1991 | 75 | 0.010 |
Why?
| | Logistic Models | 1 | 1996 | 2074 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1995 | 2057 | 0.010 |
Why?
| | Macrophages | 1 | 1998 | 1547 | 0.010 |
Why?
| | Drug Interactions | 1 | 1991 | 410 | 0.010 |
Why?
| | Clinical Protocols | 1 | 1991 | 271 | 0.010 |
Why?
| | Registries | 1 | 1997 | 2035 | 0.000 |
Why?
| | Hypertension | 1 | 1998 | 1295 | 0.000 |
Why?
| | Sensitivity and Specificity | 1 | 1994 | 1946 | 0.000 |
Why?
| | Transforming Growth Factor beta | 1 | 1991 | 480 | 0.000 |
Why?
| | Emergency Service, Hospital | 1 | 2000 | 2069 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1993 | 625 | 0.000 |
Why?
| | Communicable Diseases | 1 | 1991 | 159 | 0.000 |
Why?
| | Erythrocytes | 1 | 1994 | 700 | 0.000 |
Why?
| | Counseling | 1 | 1991 | 391 | 0.000 |
Why?
| | Immunity, Innate | 1 | 1994 | 828 | 0.000 |
Why?
| | Analysis of Variance | 1 | 1991 | 1316 | 0.000 |
Why?
| | Flow Cytometry | 1 | 1991 | 1178 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 2071 | 0.000 |
Why?
| | Myocardial Infarction | 1 | 1993 | 1046 | 0.000 |
Why?
| | Biomarkers | 1 | 1997 | 4149 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1991 | 1430 | 0.000 |
Why?
| | Quality of Life | 1 | 1996 | 2892 | 0.000 |
Why?
| | Tomography, X-Ray Computed | 1 | 1993 | 2691 | 0.000 |
Why?
| | Mass Screening | 1 | 1991 | 1287 | 0.000 |
Why?
|
|
Gundry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|